US$ 29.57
companies innovating in obesity treatment glp-1 drugs 2025 The everything drugs: from weight loss to whole body medicines GLP-1 Receptor Agonist Market Size,
Description
doi: 10.1172/JCI105714 7 UngerRHEisentrautAMMcCMMadisonLL

Vahedi K, Taupin P, Djomby R, et al

The missed expectations on Mounjaro and Zepbound sales compelled David Risinger of Leerink Partners to lower his firms 12-month price target on Lilly shares but only by 2%, from $990 to $970, though he maintained his firms Outperform rating on the stock

That, combined with possible nutritional deficiencies from eating less, could lead to shedding

Int J Obes (Lond) 2025;49(3):433451

Market Statistics Key Takeaways By type of GLP-1 agonist drugs, the long-acting GLP-1 agonist segment dominated in 2025
